BioAffinity Technologies (BIAF) announced sales of its CyPath Lung diagnostic test for lung cancer reached a new high in the third quarter of 2025, representing a 95% increase over the previous quarter. The increase reflects growing adoption by Veterans’ hospitals and market expansion in the mid-Atlantic region. In the first nine months of 2025, sales of CyPath Lung rose 97% over the same period in 2024.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIAF:
- bioAffinity Technologies Completes $4.8M Stock Offering
- BioAffinity prices 1.92M common share offering at $2.50 per share
- bioAffinity Technologies Inc trading resumes
- bioAffinity Technologies Inc trading halted, volatility trading pause
- BioAffinity Technologies files to sell 729,927 shares of common stock